Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Sarepta Therapeutics, Inc.”

102 pharma patents match "Sarepta Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 102
Index total 30,257
Page 4 / 5

Quick answer

This filtered view shows 102 pharmaceutical patents matching "Sarepta Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

102 results for “Sarepta Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 9416361

    Splice-region antisense composition and method

    Sarepta Therapeutics, Inc. · Granted Aug 16, 2016 · Expires Aug 11, 2036

    granted

  2. US 9394323

    Antisense antiviral compound and method for treating influenza viral infection

    Sarepta Therapeutics, Inc. · Granted Jul 19, 2016 · Expires Jul 14, 2036

    granted

  3. US 9382536

    Antisense antiviral compounds and methods for treating a filovirus infection

    Sarepta Therapeutics, Inc. · Granted Jul 5, 2016 · Expires Jun 30, 2036

    granted

  4. US 9347063

    Oligonucleotide analog and method for treating flavivirus infections

    Sarepta Therapeutics, Inc. · Granted May 24, 2016 · Expires May 19, 2036

    granted

  5. US 9278987

    Functionally-modified oligonucleotides and subunits thereof

    Sarepta Therapeutics, Inc. · Granted Mar 8, 2016 · Expires Mar 3, 2036

    granted

  6. US 9249243

    Antibacterial antisense oligonucleotide and method

    Sarepta Therapeutics, Inc. · Granted Feb 2, 2016 · Expires Jan 28, 2036

    granted

  7. US 9238042

    Antisense modulation of interleukins 17 and 23 signaling

    Sarepta Therapeutics, Inc. · Granted Jan 19, 2016 · Expires Jan 14, 2036

    granted

  8. US 9234198

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted

  9. US 9217148

    Exon skipping compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Dec 22, 2015 · Expires Dec 17, 2035

    granted

  10. US 9161948

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Oct 20, 2015 · Expires Oct 15, 2035

    granted

  11. US 9066967

    Oligonucleotide analogues targeting human LMNA

    Sarepta Therapeutics, Inc. · Granted Jun 30, 2015 · Expires Jun 25, 2035

    granted

  12. US 9068185

    Antisense modulation of nuclear hormone receptors

    Sarepta Therapeutics, Inc. · Granted Jun 30, 2015 · Expires Jun 25, 2035

    granted

  13. US 8933216

    Immunosuppression compound and treatment method

    Sarepta Therapeutics, Inc. · Granted Jan 13, 2015 · Expires Jan 8, 2035

    granted

  14. US 8906872

    Antisense antiviral compound and method for treating ssRNA viral infection

    Sarepta Therapeutics, Inc. · Granted Dec 9, 2014 · Expires Dec 4, 2034

    granted

  15. US 8895722

    Splice-region antisense composition and method

    Sarepta Therapeutics, Inc. · Granted Nov 25, 2014 · Expires Nov 20, 2034

    granted

  16. US 8877725

    Peptide conjugated, inosine-substituted antisense oligomer compound and method

    Sarepta Therapeutics, Inc. · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted

  17. US 8871918

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Oct 28, 2014 · Expires Oct 23, 2034

    granted

  18. US 8865883

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Oct 21, 2014 · Expires Oct 16, 2034

    granted

  19. US 8835402

    Compound and method for treating myotonic dystrophy

    Sarepta Therapeutics, Inc. · Granted Sep 16, 2014 · Expires Sep 11, 2034

    granted

  20. US 8785407

    Antisense antiviral agent and method for treating ssRNA viral infection

    Sarepta Therapeutics, Inc. · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted

  21. US 8785410

    Antisense composition and method for treating muscle atrophy

    Sarepta Therapeutics, Inc. · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted

  22. US 8779128

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Sarepta Therapeutics, Inc. · Granted Jul 15, 2014 · Expires Jul 10, 2034

    granted

  23. US 8741863

    Compound and method for treating myotonic dystrophy

    Sarepta Therapeutics, Inc. · Granted Jun 3, 2014 · Expires May 29, 2034

    granted

  24. US 8703735

    Antisense antiviral compounds and methods for treating a filovirus infection

    Sarepta Therapeutics, Inc. · Granted Apr 22, 2014 · Expires Apr 17, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.